ArticleQuantitative imaging in medicine and surgery2025
Utilizing temporal information to assess metabolic heterogeneity: a study of
Article in Quantitative imaging in medicine and surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- From imaging heterogeneity to clinical decision: a novel imaging biomarker based on bone marrow kinetics for advanced NSCLC patients in partial response.EJNMMI research · 2026Article
- Metabolic reprogramming orchestrates an immunosuppressive microenvironment in anaplastic thyroid cancer: mechanisms and clinical perspectives.Frontiers in immunology · 2026Review
- Diagnostic and Prognostic Applications of PET/CT in Small-cell Lung Cancer.Cancer diagnosis & prognosisReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Extensive-stage small cell lung cancer (ES-SCLC) comprises most SCLC cases, with up to 40% of patients failing to achieve an objective response (OR) to first-line treatment. The prognostic value of conventional fluorine-18 fluorodeoxyglucose ( Methods: This prospective pilot cohort study enrolled 15 patients with SCLC who planned to undergo dynamic PET imaging (November 2022 to January 2024). All participants underwent dynamic PET imaging before receiving first-line treatment. Tumor regions of interest (ROIs) were delineated on the PET images to facilitate the calculation of TAC. From these curves, 6 dynamic features were derived. The Mann-Whitney U test was applied to evaluate the significance of variations in continuous variables, encompassing both TAC features and conventional metabolic parameters. Statistically significant features were used to distinguish between the OR group and the non-objective response (non-OR) group and the area under the receiver operating characteristic curve (AUC) was calculated. Results: A total of 10 patients were included for analysis. Clinical characteristics such as age, gender, smoking history, and treatment regimens were similar between the OR and non-OR groups. Analyses of conventional metabolic features [SUXmax, minimum standardized uptake value (SUVmin), mean standardized uptake value (SUVmean), metabolic tumor volume (MTV), and total lesion glycolysis (TLG)] did not reveal significant differences between the groups (all P>0.05), with MTV showing a trend towards significance (P=0.095). Among the TAC features, the slope of the TAC between 10 to 30 minutes ( Conclusions: The TAC feature (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.